Statement Of Financial Position [Abstract]

Egetis Therapeutics - Filing #5995613

Concept As at
2024-12-31
As at
2024-12-31
As at
2024-12-31
As at
2024-12-31
As at
2024-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
Statement of financial position [abstract]
Assets [abstract]
Right-of-use assets
26,000,000 SEK
43,000,000 SEK
Deferred tax assets
6,000,000 SEK
- SEK
Cash and cash equivalents
3,510,000,000 SEK
3,033,000,000 SEK
1,277,000,000 SEK
Assets
7,923,000,000 SEK
7,602,000,000 SEK
Equity and liabilities [abstract]
Equity [abstract]
Issued capital
204,000,000 SEK
154,000,000 SEK
Retained earnings
1 610,1 SEK
1 266,5 SEK
Other reserves
248,000,000 SEK
167,000,000 SEK
Equity
1 610,1 SEK
2 057,7 SEK
248,000,000 SEK
4,929,000,000 SEK
204,000,000 SEK
154,000,000 SEK
1 780,0 SEK
1 266,5 SEK
5,456,000,000 SEK
167,000,000 SEK
5,062,000,000 SEK
113,000,000 SEK
9,396,000,000 SEK
61,000,000 SEK
1 428,4 SEK
Liabilities [abstract]
Deferred tax liabilities
5,000,000 SEK
- SEK
Equity and liabilities
7,923,000,000 SEK
7,602,000,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.